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Human immunodeﬁciency virus type 1 (HIV-1) is the etiological agent of AIDS. Chronic persistent
infection is an important reason for the presence of ‘‘latent cell populations’’ even after Anti-Retroviral
Therapy (ART). We have analyzed the effect of ATP analogs in inhibiting cdk9/T1 complex in infected
cells. A third generation drug named CR8#13 is an effective inhibitor of Tat activated transcription.
Following drug treatment, we observed a decreased loading of cdk9 onto the HIV-1 DNA. We found
multiple novel cdk9/T1 complexes present in infected and uninfected cells with one complex being
unique to infected cells. This complex is sensitive to CR8#13 in kinase assays. Treatment of PBMC with
CR8#13 does not kill infected cells as compared to Flavopiridol. Interestingly, there is a difference in
sensitivity of various clades to these analogs. Collectively, these results point to targeting novel
complexes for inhibition of cellular proteins that are unique to infected cells.
& 2012 Elsevier Inc. All rights reserved.Introduction
As of the end of 2008, there were an estimated 40–100 million
people living with human immunodeﬁciency virus type 1 (HIV-1),
globally. The development of an additional 18,000 new HIV-1
infections were calculated to take place daily, with 95% of these
cases occurring in developing countries and 50% in women. Current
projections suggest continued increase in the number of people
infected with a possible resurgence of this pandemic in high-income
countries, such as the United States. One possible reason for this
resurgence is the problems associated with highly active anti-
retroviral therapies (HAART) in HIV-1 treatment. HAART, a multi-
drug therapy given to AIDS patients, has proven to be effective at
lowering viral loads (o50 copies/ml in plasma) and improving an
individual’s immune response to HIV-1 infection. However, limita-
tions and concerns regarding cost, complexity of treatment, and
long-term side effects have led to lower adherence to treatment
regimens by some patients. Also, the development of drug-resistantll rights reserved.
).mutants, either through a lack of protocol adherence or supervised/
structured treatment interruptions (STIs), has increasingly become
problematic (De Clercq, 2002; Simon et al., 2002).
Today, it is widely believed that the success of HIV-1 treatment
will require targeting of other HIV-1 and/or host cellular proteins. To
that end, we focused on inhibiting Tat activated HIV-1 transcription
and post transcription events, as well as the interaction of Tat with
the host cell cycle proteins. HIV-1 Tat interacts with many cellular
factors, which may or may not be important for HIV-1 or cellular
transcription. However, cdk9/cyclin T1 (P-TEFb) complex has
emerged as the most important Tat binding partner that induces
elongation of transcription from the HIV-1 LTR.
Expression of the HIV-1 proviral genome requires host cell
transcription factors as well as a viral transactivator (Tat) protein
(Greene and Peterlin, 2002; Karn, 1999; Karn and Stoltzfus, 2012;
Mbonye and Karn, 2011). Tat stimulates formation of full-length
transcripts from the HIV-1 promoter (Adams et al., 1994; Antoni et al.,
1994) by promoting efﬁcient transcript elongation (Greene and
Peterlin, 2002; Karn, 1999). Tat associates with cdk9 (Yang et al.,
1997; Zhu et al., 1997) through interaction with the cyclin partner,
cyclin T1. Cyclin T1, in turn, interacts with the loop of TAR RNA (Wei
et al., 1998). Also, the levels of cyclin T1 are dramatically up-regulated
A. Narayanan et al. / Virology 432 (2012) 219–231220by two independent signaling pathways triggered by PMA and PHA in
primary human PBLs, inducing these cells to enter and progress
through the cell cycle (Garriga et al., 1998). Furthermore, cdk9
expression during the cell cycle is periodic and peaks at the G1/S
border (Garriga et al., 2003; Kiernan et al., 2001), and cyclin T1 levels
are dramatically reduced when cells are blocked at the G1/S phase of
cell cycle (Kashanchi, unpublished data). Also, a growing body of
evidence has indicated the role of yet another cdk/cyclin complex,
namely cdk2/cyclin E, in Tat activated transcription. Cdk2/cyclin E is
the major cdk/cyclin complex whose maximal activity is observed at
the late G1/S boundary. In vivo studies on the involvement of the G1/S
phase and cdk2 in HLM1 cells (HIV-1þ/Tat) have shown that Tat
transfected cells produced far more infectious virus when blocked at
G2/M as compared to G1/S (Ammosova et al., 2005, 2006; de la
Fuente et al., 2003; Debebe et al., 2011; Kapasi and Spector, 2008;
Nekhai et al., 2002).
Pharmacological inhibitors such as Flavopiridol represent the
ﬁrst-generation of selective cdk inhibitors, with 50% inhibitory
concentrations (IC50) of 40–400 nM for all cdks tested (Dai and
Grant, 2004). Interestingly, Flavopiridol tightly binds to cdk9 and
inhibits Tat-dependent transcription in vitro as well as inhibiting
HIV-1 replication in cultured cells (Chao et al., 2000). The second
generation of cdk inhibitors such as R-roscovitine, blocks HIV-1
replication in chronically infected cells (Wang et al., 2001),
possibly by directly blocking the activity of all three cdk/cyclin
complexes. We recently used R-roscovitine (CYC202) and the acid
metabolite M-CYC202 control and showed a potent transcrip-
tional inhibition on the HIV-1 genome with low IC50 values. We
also generated a 2nd and 3rd generation CYC202 inhibitor with
potent activity against HIV-1. The 2nd generation drug, named
CR8, was previously tested and found to effectively inhibit HIV-1
transcription (Guendel et al., 2010) and effectively kill infected
cells. An analog of CR8, named CR8#13 (BJFP1154), was unique in
that it displayed very little cytotoxicity toward infected cells,
while causing the most signiﬁcant decrease of HIV-1 transcription
in HeLa cells (Carpio et al., 2010). Here we extend the effect and
mechanism of CR8#13 in more depth in HIV-1 infected primary
cells as well as multiple strains and clades of HIV-1. We also
report on the presence of multiple novel cdk9 complexes, one of
which is only present in HIV-1 infected cells. This complex can
selectively be inhibited using ATP analogs.Results
3rd generation ATP analog inhibits HIV-1 activated transcription
We have previously shown that a set of drugs derived from
2,6,9-trisubstituted cdk inhibitory purines as well as 6-amino-
methylenebiaryl analogs of CYC202 can down regulate HIV-1
activity (Carpio et al., 2010; Oumata et al., 2008). Among these
inhibitors, CR8, an analog bearing a 2-pyridyl on position 4 of itsFig. 1. Effect of CR8#13 on the HIV-1 Promoter in cells: (A) early to mid log phase CEM c
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electroporated with 5 mg of either CMV-CAT, LTR-CAT (DNF-kB), or LTR-CAT (DTAR; TM
and CAT assay performed 48 h later. Ten microgram of total extract was used for b-act
with 25 mg of a-cdk9 antibody for immunoprecipitation. Samples were incubated over
twice with TNE150þ0.1% NP-40 and twice kinase buffer. The IPed material was divided
tube. Samples were incubated for 30 min/37 1C followed by separation on 4–20% SDS
kinase reactions. Flavopiridol (10 nM) was used as a control. Counts are from Molecular
and a-cdk4 antibodies were used for immunoprecipitation overnight followed by in v
50 nM of CR8#13 was used for in vitro assay. The ‘‘K’’ units are in counts of 1000 fro
cytosolic extract and nuclear pellet, respectively.phenyl ring, was created (Galons et al., 2010). Among the 18 CR8
derivatives tested in vitro, the compound CR8#13 (BJFP1154),
exhibited the greatest transcriptional inhibition of the HIV-1 LTR
in HeLa cells with no apparent cell toxicity. Here, we have
extended the studies on the CR8#13 to better deﬁne the range
of inhibition and other possible modes of action in HIV-1
infected cells.
We initially tested the effect of two CR8 derivatives in cells
transfected with a LTR-CAT reporter and asked whether Tat
activated transcription could be inhibited by these ATP analogs.
Data in Fig. 1A show a titration of two drugs, CR8#1 (MRT033)
and CR8#13, where low concentration of CR8#13 (50 nM, Lane 6)
was effectively able to inhibit Tat activated transcription. The
inhibition with CR8#13 was similar to a well known cdk9
inhibitor, Flavopiridol (50 nM, Lane 3). Cells treated with a low
concentration of these drugs were not affected as measured by
PARP western blot or changes in a few well known cdk9 regulated
endogenous genes including CIITA, IL-8, CAD, MCL-1 and cyclin D
(data not shown).
We next examined the effect of both CR8#1 (control) and the
CR8#13 (experimental) in HIV-1 latent cells. For this we utilized
OM10.1 cells, where wild type virus is silent, and where addition
of TNF-a activates the virus. The OM10.1 cells (promyelocytic)
were ﬁrst transfected with LTR-CAT, followed by treatment of
transfected cells with TNF-a for 2 h and then either CR8#1 or
CR8#13 (50 and 100 nM) were added to the media for 48 h. Here,
the assumption is that as a result of TNF-a addition, the produc-
tion of Tat mRNA and protein will activate the exogenously added
LTR-CAT construct. As seen in Fig. 1B, the construct was effec-
tively activated in these cells (Lane #1). Treatment of cells with
Flavopiridol or CR8#13 (50 nM) effectively wiped out transcrip-
tion (Lanes 2 and 5) of LTR-CAT in these cells. A western blot
performed using a b-actin antibody for both cell types (CEM and
OM10.1) showed no change in the protein levels in these
transient transfection experiments.
As another set of controls, we transfected LTR-CAT construct
into OM10.1 cells without TNF-a activation. Here the rationale
was to score only for basal transcription and not Tat activated
transcription (from the endogenous virus). Results in Panel C
show that there was basal transcription of LTR in these cells and
an increasing concentration of CR8#13 (50 and 100 nM) caused
only a modest reduction in basal transcription. We also per-
formed another set of control experiments in CEM cells with
constructs that were either a HIV-LTR NF-kB mutant, a TAR
mutant (TM26; generous gift of Dr. A. Kumar; Zhou et al., 2004)
or a CMV-CAT construct. Following transfection, cells were
treated with CR8#13 and results in Panel D showed that, again,
the level of inhibition on these constructs was less than 2 fold.
This further argues that the CR8#13 may be unique to Tat
activated transcription on wild type LTR.
We next asked whether these drugs could potentially inhibit cdk9
kinase activity in vitro. For that, we used cdk9 immunoprecipitatedells were electroporated with either LTR-CAT alone (5 mg) or with CMV-Tat (Pc Tat;
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26). Samples were treated with CR8#13 (100 nM) immediately after transfection
in western blot. (E) Total cell extracts (TNF-a treated OM10.1; 2.5 mg) were used
night at 4 1C and protein AþG added next day for 2 h. IPed material was washed
into 6 tubes with histone H1, kinase reaction mix, and drugs were added to each
/PAGE. Two concentrations of CR8#1 and CR8#13 (10 and 50 nM) were used for
Dynamics phosphorimager analysis. (F) Similar to Panel E, where 10 mg of a-cdk2
itro kinase assay next day using histone H1 as substrate. A ﬁnal concentration of
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and incubated them with histone H1 as a substrate. A number of
substrates including histone H1 have been shown to be phosphory-
lated by cdk9 (O’Brien et al., 2010, 2012; Tian et al., 2012). Results in
Panel E show that CR8#13 (10 and 50 nM; Lanes 4 and 5) effectively
inhibited cdk9 activity to similar levels as Flavopiridol (10 nM; Lane
6). Similar results were also observed when cdk9 was immunopre-
cipitated and analyzed by kinase assays with a CTD substrate (data
not shown). Finally, we performed a similar experiment with active
cdk2 and cdk4 enzymes immunoprecipitated from TNF-a treated
OM10.1 cells followed by in vitro kinase assays. Results in Panel F
show that CR8#13 selectively inhibits cdk9 but not cdk2 or cdk4
when isolated from infected cells. Collectively, these results recon-
ﬁrm that CR8#13 is an effective inhibitor of Tat activated transcrip-
tion in T-cells and other cell types.
Effect of CR8#13 on loading of cdk9 complex and its localization
We have previously shown that the 2nd generation drug,
CYC202, was able to inhibit HIV-1 transcription by interfering
with loading of cdk9, but not cdk4, onto the HIV-1 genome
(Agbottah et al., 2005). We speciﬁcally showed that siRNA inter-
ference followed by ChIP can be used to measure the binding of
various cdk/cyclin complexes loaded onto the HIV-1 DNA in vivo
(proof of principle experiments) and that CYC202 inhibited
loading of cdk9 onto the LTR and Env regions. We therefore asked
whether CR8#13 or the control CR8#1 could effectively down
regulate levels of cdk9 protein on the LTR or the Env regions.
Results in Fig. 2, Panel A show that when cells are treated with
CR8#13, there is an appreciable drop of cdk9 and Pol II on the LTR
region (lanes 3 and 5). More importantly, these proteins were
completely absent on the envelope region when treated with
CR8#13. A dilution of PCR products (2 fold) was resolved on
ethidium bromide containing agarose gels and relative signal
intensities were measured using a phosphorimager. Measured
signal intensities indicated a linear drop in the immunoprecipi-
tated material for both LTR and Env regions. Finally, treatment
with CR8#13 at these low concentrations did not push cells into
apoptosis, as shown by the number of live cells in these 48 h
treatment experiment. Similar results were obtained when the
relative numbers of live cells were measured using CellTiter-Glo
assay from these drug treated cells (Panel C). Collectively, these
results imply that CR8#13 is able to inhibit uploading of cdk9 and
Pol II onto LTR and Env regions.
In 2007, a collaborative work between three labs (Maury, Price
and Bensaude) showed that there are two forms of the cdk9/T1
complexes and they could be physically separated in HeLa cells
when using any of the three cdk inhibitors including Flavopiridol
(Alvocidib), DRB (5,6-dichloro-1-b-D-ribofuranosylbenzimidazole)
or R-roscovitine (Seliciclib/CYC202) (Biglione et al., 2007). They
also developed a rapid salt extraction assay that allowed them to
determine the amount of large and free forms of cdk9/T1 present
in cells. As controls, the differential salt extractability of the TFIIH
subunits p62, cdk7 and cyclin H showed no change in nuclear vs.
cytoplasmic fractions after drug treatment. Therefore, we decided
to pursue similar experiments with CR8#13, and asked whether
cdk9 localization was also altered in these drug treated cells. We
treated cells with either DRB (100 mM, as positive control) or with
CR8#13 (50 nM, experimental). We isolated cytoplasmic, as well
as nuclear extracts and used differential salt extractions (0 and
200 mM), which were subsequently Western blotted for the
presence of cdk9, cyclin T1, cdk7 and cyclin H in these extracts.
Results in Fig. 2, Panel D show that CR8#13 treated cells behaved
very similarly to DRB treatment, and most of the cdk9 in CR8#13
treated cells became part of the large inactive cdk9 complex
(lanes 3 and 4). We have consistently observed some 1–5% ofcdk9 still remains in the nucleus when cells are either treated
with DRB or CR8#13. We observed very little change in the cyclin
T1 distribution in cytoplasmic vs. nuclear fractions in these
HIV-1 infected OM10.1 cells. The only signiﬁcant difference was
at high salt (which extracts both large and free complexes) in
drug treated cells, where the majority of cyclin T1 did not enter
the nucleus (Lane 4). Interestingly, data for cdk7 and cyclin H
were somewhat similar to HeLa data from Biglione et al. where
salt extractability of these proteins was unaffected by the addi-
tion of CR8#13. Collectively, these results imply that the majority
of the cdk9 is most likely unable to move to the nucleus when
treated with these transcription inhibitors in infected cells and
that may partially explain the loss of loading of cdk9 onto the
HIV-1 DNA.Presence of a novel small complex in HIV-1 infected cells
We next asked whether infected cells that express virus on a
continuous basis would have a novel cdk9/T1 complex that may be
differentially regulated by CR8#13. Here we used parental unin-
fected (Jurkat) and LAI infected Jurkat (J1-1) cells for separation of
various cdk9 and cyclin T1 complexes. We used cells at early–mid
log phase of growth and prepared total protein using Lysate buffer.
The samples were then loaded onto a sizing column in the presence
of high salt to minimize non-speciﬁc binding (500 mM NaCl). FPLC
fractions were then precipitated and used for western blot analysis
and kinase assays. Results of such an experiment are shown in Fig. 3,
where Jurkat uninfected fractions showed cyclin T1 complexes in
fractions 15–35 and a similar proﬁle was observed for cdk9 (Panel
A). We performed Western blot analyses for Hexim 1 (inhibitor of
P-TEFb), ELL2 (component of the super elongation complex) (He
et al., 2010; Sobhian et al., 2010), Brd4 (cellular analog of HIV-1 Tat
protein which activates cellular genes when complexed with cdk9/
T1 complex), and RT/PCR for 7SK RNA (an abundant RNA molecule
that, when bound to MePCE, LARP7, Hexim 1, and cdk9/T1 proteins,
forms the large inactive complex called ‘‘7SK SNRNP Complex’’).
Results show that Hexim 1 eluted mostly at fractions 25–35; ELL2
eluted mostly at fractions 30–40; and Brd4 at fractions 20–30. It is
interesting to note that both ELL2 and especially Brd4 did not elute
from the WCE preps indicating that these proteins are mostly
nuclear and bound to chromatin DNA (insoluble complexes). Inter-
esting results were obtained with 7SK RT/PCR where the majority of
the RNA molecule eluted at fraction 25. Based on these results we
categorized the cdk9/T1 complexes as complex I (high molecular
weight of 2.2 MDa with minimal 7SK or Hexim 1), complex II
(molecular weight of 670 kDa with maximum 7SK and Hexim 1),
complex III (molecular weight of 450 kDa with minimal 7SK and
highest b-actin) and complex IV (molecular weight of 100 kDa
with minimal Hexim 1 and low b-actin). It is important to note that
the high amount of protein (peak of the bell shape curve) was
present at fraction # 30 (data not shown).
When examining the HIV-1 infected J1-1 cells (Fig. 3, Panel B),
we observed a similar pattern for complexes I–III with some
notable differences. For instance, the overall level of ELL2 in
infected cells which was soluble was higher than uninfected cells,
and the overall level of Brd4 was generally lower in infected cells
(compare Lanes 1 and fractions between Jurkat and J1-1). There
was also a dramatic increase in the 7SK levels in the infected
cells in complex II in infected vs. uninfected cells. These results
imply that when assaying for active P-TEFb complexes in HIV-1
infected cells, there needs to be a comprehensive examination of
the components that control cdk9/T1 activity including the
proteins tested here. Finally, complex IV was mostly abundant
in infected cells and reduced (especially for cyclin T1) in
uninfected cells.
α-cdk9 α-pol II
LTR
Ig
G
In
pu
t
C
R
8 
#1
3
C
R
8 
#1
C
R
8 
#1
3
C
R
8 
#1
% live cells
1 2 3 4 5 6
- - 92 86 88 94
Env
9.0E+06
5.0E+06
6.0E+06
7.0E+06
8.0E+06
1.0E+06
2.0E+06
3.0E+06
4.0E+06
Lu
m
in
es
ce
nc
e
Infected Infected
+ CR8#1
Infected
+ CR8#13
LTR Env
α -cdk9
CR8#13
α -cdk9
CR8#1
α -Pol II
CR8#1
α -Pol II
CR8#13 α -cdk9
CR8#13
α -cdk9
CR8#1
α -Pol II
CR8#1
α -Pol II
CR8#13
10
15
20
0
5
A
rb
itr
ar
y 
N
um
be
rs
40
50
60
0
10
20
30
A
rb
itr
ar
y 
N
um
be
rs
DilutionDilution
CE
NP
CE
NP
CE
NP
CR8#13
1      2           3     4
cdk9
CycT1
Cyc H
cdk7
CE
NP
DRB
0 200
- + - +
mM NaCl
CE
NP
Fig. 2. Effect of CR8#13 on cdk9 and Pol II occupancy on the HIV-1 genome: (A) inhibition of loading of cdk9 and Pol II onto the HIV-1 genome when using CR8#13 or
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as J1-1cells treated with this drug dramatically shifted complex IV
to complex III for cdk9 and cyclin T1 (Fig. 3, Panel C). We also
observed movement of cdk9 larger complexes to complex III and
an overall reduction in Hexim 1 and its concentration in complex
III. Therefore, complexes IV and possibly complex I may be the
true target of Flavopiridol in HIV-1 infected cells.We next performed a transfection of wild type HIV-1 plasmid
(pNL4-3) into Jurkat cells (for 5 days) and fractionated the whole
cell extract over the sizing column. We were interested to see if
we could detect the smaller complex IV in these cells. Results
in Panel D show that both cyclin T1 and cdk9 were present
in fractions 36 (complex III) and 46 (complex IV) from infected
cells.
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sequence. Results are presented as a mean of two independent measurements and shown as a percent of max RNA count. Error bars show the standard error of mean
values. Equal volumes of samples (half of each 500 ml fraction) were processed for western blots. Molecular weight markers of known positive controls were used to
determine the range and size of the complexes. (B) Similar to Panel A, however, J1-1 cell extracts were used for fractionations and then western blotted for presence of
cyclin T1, cdk9, Hexim 1, ELL2, Brd4, p24 and b-actin. Similar RT/PCR was performed for 7SK RNA. A total of 4 complexes designated as complexes I, II, III and IV were
observed in HIV-1 infected cells. (C) HIV-1 infected J1-1 cells were treated with Flavopiridol (100 nM) and sample were processed for chromatography after 48 h. Western
blots were performed for cdk9, cyclin T1 and Hexim 1 and b-actin. (D) Mid-log growing Jurkat cells were transfected with 20 mg of wild type pNL4-3 plasmid and samples
were processed 5 days later for sizing column chromatography. Fractions representing complexes II (#26), III (#36), and IV (#46) were precipitated using acetone, dried
and western blotted with antibodies against cyclin T1, cdk9, and b-actin. (E) Kinase assay using cdk9 immunoprecipitates (J1-1 and Jurkat) followed by phosphorylation of
GST-CTD. IgG immunoprecipitates of fractions 30 and 45 from both infected and uninfected cells were used as a control. CR8#13 at 10 nM concentration was used in lanes
9 and 11.
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complexes III and IV by immunoprecipitating fractions 30 and 45
from infected and uninfected cells and used them in an in vitro
kinase assay using RNA Pol II CTD as a substrate. Results in Panel E
show that both fractions # 30 from Jurkat and J1-1 were kinase
active; however, only fraction #45 showed appreciable activity
from J1-1 fractions (compare 4 and 6). Finally, we used CR8#13 in
these in vitro kinase assays and were able to efﬁciently inhibit
activity of cdk9 from fraction #45 (Lanes 10 and 11). Collectively,
these results suggest that a novel cdk9/T1 complex may be
present in HIV-1 infected cells that actively produce virus and
that the CR8#13 at low concentrations could inhibit the kinase
activity of this complex.Decreased activity of cdk9 also regulates HIV-1 splicing
In recent years, cdk9 has been associated with not only tran-
scription, but also splicing through CTD and other proteins (Bres
et al., 2008; Lin et al., 2008; Mapendano et al., 2010; Pirngruber
et al., 2009). RNA Pol II CTD functions both, as an assembly platform
for and as a regulator of the transcription and pre-mRNA processing
machineries. During transcription initiation, serine 5 of the CTD
heptad repeat is phosphorylated to recruit capping enzymes.
Serine 2 of the heptad repeat is then phosphorylated, leading to
the recruitment of factors such as human SPT5 (hSPT5) and Tat-SF1
that are involved in subsequent steps needed for elongation
and RNA splicing. Along these lines, we have previously shown that
RNA Pol II CTD is phosphorylated at both serine 2 and 5 in the
presence of Tat resulting in altered cdk9 substrate speciﬁcity (Zhou
et al., 2003).5’ 3’
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Fig. 4. Effects of CR8#13 on HIV-1 splicing: (A) schematic of the pNLEnv plasmid. Envelo
mRNA. (B) 293T cells were transfected with pc-Tat plasmid (1 mg) and/or CR8#13 (10 nM
3 days. Actin was used as control. To detect RNA levels of Nef and Env after drug trea
regions. Total RNA samples were stained with ethidium bromide and run on a 2% denat
cells and treated with CR8#13 (10 nM) for 3 days. Soluble nuclear proteins were obtain
with a-Tat rabbit polyclonal antibody (5 mg; generous gift from Dr. Bryan Cullen; ZhouThe Caputi lab has previously published convincing data on
the effect of Tat and splicing (Jablonski et al., 2010) that is
consistent with our previous results of how Tat could modulate
not only transcription but also HIV-1 splicing through mechan-
isms, such as acetylation of lysine residues (Berro et al., 2008).
The association with both elongation and splicing factors has led
to the suggestion that factors such as Tat-SF1 can couple these
two processes (Chen et al., 2009; Kim et al., 1999; Miller et al.,
2009). Tat-SF1 has been shown to be associated with other
transcription regulators such as Tat-CT1 and the transcription–
splicing coupling factor, CA150 (Zhou et al., 1998). Tat-SF1 and
hSPT5 are required for optimal Tat activation, as shown by
immunodepletion with speciﬁc sera and complementation with
recombinant proteins (Parada and Roeder, 1999). Expression of
Tat-SF1 and hSPT5 speciﬁcally stimulates the transcriptional
activity of Tat and modulates transcription elongation and spli-
cing of HIV-1 RNA.
To show whether treatment with CR8#13 leads to not only
regulation of transcription but also splicing, we performed an
experiment using a HIV-1 vector with differential splicing pat-
terns. In the plasmid pNLEnv, the Env gene is expressed from an
unspliced mRNA, whereas Nef is made from a spliced mRNA
(Fig. 4, Panel A). We transfected 293T cells with pNLEnv DNA
along with Tat alone or Tat plus CR8#13. The production of Nef
and Env proteins were determined by Western blot analysis.
Results in Fig. 4, Panel B show that CR8#13 was able to increase
doubly spliced Nef and lower Env proteins. This change in splicing
pattern was Tat speciﬁc, since in the absence of Tat we observed
virtually no rate of transcription or splicing. When testing for b-
actin, we observed similar levels of proteins from both extracts.
The total amount of RNA from these cells also did not change+- +-CR8#13
Nef
+Tat 
+pNLEnv
+--
+ ++
Env
β-Actin
1         2 3 4
pe gene is expressed from an unspliced mRNA, whereas Nef is made from a spliced
). Western blot analysis using antibodies against Nef, or Env were performed after
tment, 100 ng of total RNA was used for cDNA synthesis and PCR for Nef and Env
uring gel. (C) pNLEnv vector (20 mg) was transfected with pc-Tat (10 mg) into 293T
ed and 50 mg of nuclear extract was run on 4–20% SDS/PAGE and western blotted
et al., 2004).
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western blot from transfected cells and were able to detect Tat
(albeit at low levels) in these cells (Panel C). Collectively, these
data indicate that factors that affect splicing may be regulated by
cdk9 and in turn may explain, at least partially, the mechanisms
of drug inhibition and downstream events leading to loss of viral
production.Effect of CR8#13 in a HIV-1 infected cell line and infected PBMCs
We next designed experiments to determine IC50 and MTT for
cells treated with a titration of CR8#13 and other inhibitors. TNF-
a activated OM10.1 cells (to activate the latent virus) wereCyc202 IC50 = 745 nM
CR8 #13 IC50 < 10 nM
CR8 IC50 = 21 nM
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Fig. 5. Effect of CR8#13 in latently infected cells and its effect in PBMCs: (A) CYC202, CR
log phase of growth and treated with TNF-a for 2 h to induce HIV-1 expression. TNF-aw
1, 10 and 100 mM in complete media. Five days later, sups were collected and processed
was carried out with Prizm software using non-liner regression curve-ﬁt of sigmoidal d
infected with THA/92/00 strain (MOI: 0.1). After 8 h, unadsorbed virus was washed a
Supernatants were collected every 3 day for RT analysis. Number of live cells was also
Similar to panel C, where PHA-activated PBMC cells (Lonza) were infected with the TH
cells. Samples were assayed using CellTiter-Glo after either 3 or 16 days.cultured for 5 days in the presence of the drug (one time
treatment only) and supernatants were collected and examined
for HIV-1 replication using p24 ELISA. The IC50 for CR8#13 was
less than 10 nM in these infected cells (Fig. 5, Panel A). These
results indicate that there is a 3 log difference between the
inhibition on HIV-1 and cellular toxicity (Fig. 5, Panel B). We next
performed similar experiments in PBMCs infected with HIV-1
Thailand strain and followed the infected PBMCs up to days 3,
6 and 9 for presence of RT in the sups and also counted the
number of live cells at each time point. We used Flavopiridol (10
and 100 nM) as positive control for inhibition of HIV-1 in these
cells. Results in Panel C show that Flavopiridol at concentration of
100 nM (lanes 4) showed clear inhibition of virus by days 6 and 9.
Similar results were obtained for CR8#13 treated cells whereCyc202 CCIC50 > 10 µM
CR8 CCIC50 > 10 µM
CR8 #13 CCIC50 > 10 µM
-10 -9 -8 -7 -6 -5
00
00
0
00
log (M)
90
00
40
50
60
70
80
0
10
20
30
1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6
Day 3 Day 6 Day 9
Day 16
6
6
6
6
6
0
6
8 and CR8#13 were used to treat activated OM10.1 cells. Cells were grown to mid-
as then removed and cells were subsequently treated with drugs at 0.001, 0.01, 0.1,
for p24 HIV-1 Gag ELISA. (B) At day 5 cells were processed for MTT assay. Analysis
ose–response with variable slope. (C) and (D) PHA-activated PBMC (5106) were
way and cells were treated with 10 or 100 nM of either Flavopiridol or CR8#13.
plotted from each date and treatment (trypan blue exclusion assay). (E) and (F)
A/92/00 strain and treated with various concentrations of Flavopiridol or CR8#13
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RT activity in the supernatant (day 9). However, a more interest-
ing story emerged when we counted the number of live cells after
infection. Results in panel D showed that Flavopiridol at 100 nM
was beginning to show increased toxicity at days 6 and 9 (above
what HIV-1 infection in PBMCs would normally show). This is
consistent with the effect of Flavopiridol in long term cultures
(Biglione et al., 2007). However, CR8#13 treated cells did not
show appreciable cell death in days 6 or 9 in these infected cells.
Finally, we performed a similar experiment with another set of
activated PBMC cells and treated these infected cells with Flavo-
piridol and CR8#13 at varying concentrations. To utilize an
alternate assay to measure viable cells, we used CellTiter-Glo
viability analysis for both early (day 3) and late (day 16) samples
(Panel E). Again we observed a better rate of survivability in cells
that were treated with CR8#13 as compared to Flavopiridol.
Collectively, these results show that when using a low concentra-
tion of CR8#13, the level of HIV-1 expression is decreased, but cell
death is not the reason for this apparent inhibition.Effect of drug treatment on HIV-1 variants
Globally circulating HIV-1 sequences have been classiﬁed as
major group M (subdivided in to 11 distinct subtypes named A–K)
and two highly divergent groups named O and N. After the ﬁrst
description of the HIV-1 recombinant isolates, a substantial
proportion of viral strains isolated from different geographical
regions have been determined to comprise inter-subtype recom-
binants, and currently available full-length sequences of isolates
classiﬁed as subtypes E, G, and I have been found to embody
different regions of distinct HIV-1 clades (Koulinska et al., 2001).
We next asked whether CR8#13 could differentially inhibit
various HIV-1 clades due to nucleotide variations in the promoter
or Tat open reading frame of these viruses. Subtype clade
variations are apparent within the promoter region and Tat of
main subtypes B, C, and E, which have been shown to include
alterations in the TATA box, the NF-kB enhancer, and the TAR
element, as well as other modulatory elements such as Sp1, USF,
and NF-AT binding sites (Jeeninga et al., 2000; Montano et al.,
1998). Also, the Tat activator from subtype E, compared to Tat B or
C, possesses the highest transactivation capacity (Roof et al., 2002).
Along these lines, we performed infections using 4 different
HIV-1 isolates. Activated PBMCs were infected with subtypes A, B,
C and CRF AB. Two hours after adsorption/infection, cells were
treated with a titration of CR8#13. Samples were collected after 7
days for RT assay. Results in Fig. 6 show that all four strains ofBA
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Fig. 6. Varying response of viral clades to CR8#13 treatment. Approximately 5106
96BW05.02; and CRF AB: KAL153 (5 ng of p24 gag antigen/virus). After 2 h of infection,
and 10 nM) was performed (only once) immediately after the addition of fresh mediumvirus had different kinetics of replication in these cells. For
instance, clade C replicated best and CRF replicated the least in
our assays. Interestingly, a titration of CR8#13 showed effective
inhibition for clades A, B and CRF but not so much for clade C
(lanes 10–12). These results are consistent with previous results
where differences with Tat half life and activity of the LTRs are
observed in these clades. (Berro et al., 2006; Campbell et al., 2010;
Desfosses et al., 2005; Gandhi et al., 2009; Li et al., 2008; Rao
et al., 2008; Roof et al., 2002; Samikkannu et al., 2009; Wong
et al., 2010). Collectively, these data indicate that transcription
inhibitors may be clade speciﬁc and the activity of both LTR and
Tat may dictate the efﬁcacy of these agents.Discussion
HIV-1 virology and pathogenetic mechanisms of infection are
continuously being investigated. A detailed understanding of HIV-
1 structure and how it establishes infection and causes AIDS are
crucial not only to identify and develop new effective drugs and
vaccines, but also to deﬁne strategies for the diagnosis of HIV
infection. Further, studies on the different viral subtypes and
recombinant forms have shown that marked differences in the
infection cycle may occur based on the phylogenetic and geo-
graphic origin of HIV-1 isolates. This is key for the design of new
preventive and therapeutic approaches aimed at counteracting
molecules essential for virus cycle. These acquisitions have also
enabled the development of novel drugs aimed at an earlier and
more accurate inhibition of virus antigens and virus speciﬁc
replication steps in biological samples.
In the current manuscript we show that 3rd generation
derivatives of R-roscovitine, such as CR8#13, are effective in
inhibiting HIV-1 replication in cell culture systems. The main
mechanism of action is at the level of LTR activation by Tat and
this inhibition is directly linked to inhibition of cdk9/T1 kinase
activity from infected cells (Fig. 1). One of the unique features of
our study is the isolation of active cdk9/T1 complex from infected
cells which may have a different set of properties/substrate
speciﬁcity compared to uninfected cells.
Our data regarding factor occupancy also show that both cdk9
and RNA Pol II uploading onto the LTR and Env region is severely
decreased in the presence of CR8#13. This may be partially
because cdk9 trafﬁcking is altered in these drug treated cells
(Fig. 2B), which further reinforces the signiﬁcance of localization
for Tat activated transcription to occur. Current studies in our lab
and a number of other labs are pursuing this line of research andCRFC
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PBMCs were infected with Subtype A: 92UG037.1; Subtype B: HxB2; Subtype C:
cells were washed and fresh medium was added. Drug treatment (CR8#13; 0.1, 1,
. Samples were collected at day 7 for RT assay.
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proteins from cytoplasm to nucleus.
When looking for substrates for CR8#13 in uninfected cells, we
were surprised to ﬁnd that a new cdk9/T1 complex may exist in
HIV-1 chronically infected cells. Data in Fig. 3 indicate that when
cells produce active virus there are multiple novel cdk9/T1 com-
plexes including a small complex that is unique to infected cells,
kinase active, and sensitive to CR8#13 treatment. This is a unique
window of opportunity to tackle cellular proteins such as cdk9/T1
that are altered as a result of infection. To our knowledge no other
lab has examined cdk9/T1 complexes that are formed in cells that
actively produce virus, making this observation fairly unique.
Western blot analysis of these fractions have shown Hexim 1 (a
negative regulator of cdk9/T1 complex) to be present in complex III
making the small complex IV more attractive as a target of
inhibition. Current proteomic experiments are in progress to deﬁne
protein partners of the cdk9 complex in complexes I–IV.
Our analysis of splicing has also shown that Tat is involved in the
regulation of mRNA (and possibly pri-microRNA such as an
extended TAR) regulation in infected cells. It is intriguing to
speculate that CR8#13 regulation of cdk9 not only controls tran-
scriptional elongation but also regulates splicing of HIV-1 mRNA in
infected cells. Finally, we have utilized CR8#13 in various infectious
settings using 3 different clades and one recombinant form of virus.
We were surprised to see that CR8#13 inhibits some clades better
than others (Fig. 6). Our current understanding of the LTR and Tat
from these clades indicates the presence of minor nucleotide
changes in LTR and increased lysine residues in some, but not all,
Tats (i.e. clade C). Therefore, regulation of LTR in these clades may
require complexes that are not always dependent on cdk9/T1
activity. This would point to an examination of various clades in
both T-cells and monocyte derived macrophages MDM for their
requirements in using cdk9/T1 complexes. Alternately, a different
cdk9/T1 complex (i.e., complex I) may be the dominant complex in
binding to clades such as clade C, which would have a different rate
of transcription, splicing events and varying sensitivity to ATP
analogs. Future experiments will determine the complexes present
on various LTRs from these clades and how they may be sensitive to
transcription inhibitors.Conclusions A third generation derivative of R-roscovitine named CR8#13
is an effective inhibitor of Tat activated transcription. CR8#13 interferes with the loading of cdk9 onto the HIV-1
promoter and this may be a critical component that contri-
butes to the anti-viral efﬁcacy of CR8#13. We have found that a novel cdk9/T1 complex that is present
only in cells that actively express and shed virus. It was
striking to observe that this novel cdk9/T1 complex is sensitive
to CR8#13 as determined by in vitro kinase assays. Treatment of PBMC with CR8#13 does not cause mortality of
infected cells in long term cultures as compared to other cdk9
inhibitors such as Flavopiridol. Finally, we show that various clades of HIV-1 may be differ-
entially sensitive to these ATP analogs.Materials and methods
Cell culture and reagents
CEM cells were obtained from ATCC (Manassas, VA). OM10.1
HIV-1 infected latent cells were obtained from the NIH AIDSResearch and Reference Reagent Program. CEM cells were cultured
and maintained in RPMI Medium 1640 containing 10% fetal bovine
serum (FBS), 1% antibiotic solution (penicillin and streptomycin),
and 1% glutamine (Invitrogen). The viability of cells was determined
by trypan blue exclusion assay. To induce HIV-1 in OM10.1 cells, the
cells were treated with TNF-a (10 ng/ml) for 2 h, and then washed
with phosphate-buffered saline (PBS). After virus stimulation, the
cells were cultured in complete media and supernatants were
collected and analyzed for presence of RT.
Phytohemagglutinin-activated PBMCs were kept in culture for 2
days prior to each infection. Isolation and treatment of PBMCs were
performed by following the guidelines of the Centers for Disease
Control. Approximately 2.5106 PBMCs were infected with various
HIV-1 strains (5 ng of p24 gag antigen). All viral isolates were
obtained from the National Institutes of Health AIDS Research and
Reference Reagent Program. After 8 h of infection, cells were washed
and fresh medium was added. Drug treatment was performed (only
once) immediately after the addition of fresh medium. Samples
were collected at various time points and stored at 20 1C for RT
assay. Histone H1 was purchased from Upstate Cell Signaling
Solutions (Charlottesville, VA). Protein (G) and protein (A) agarose
were purchased from Sigma (Atlanta, GA).Transfections and CAT assays
HIV-1 LTR chloramphenicol acetyltransferase (CAT) and pcTat
have previously been described (Agbottah et al., 2005, 2006; Berro
et al., 2006; Kashanchi et al., 1994). HIV-LTR-CAT (5 mg) and CMV-
Tat (1.5 mg) vectors were electroporated into CEM cells as described
previously (Kashanchi et al., 1992). Extracts were prepared 18 h
later for CAT assay. Cells were harvested, washed once with
phosphate-buffered saline (PBS) without Ca2þ and Mg2þ , pelleted,
and resuspended in 150 ml of 0.25 M Tris (pH 7.8). The cells were
freeze-thawed three times, with vortexing after each thawing. The
tubes were incubated for 5 min at 68 1C and then centrifuged. The
supernatants were transferred to 1.5-ml Eppendorf tubes. After one
ﬁnal spin, the supernatant was again transferred to 1.5-ml Eppen-
dorf tubes and the protein concentration was determined. CAT
assays were performed with 10 mg of protein.Kinase assay
Cells were washed with PBS, and whole-cell lysates were
prepared from the cells using whole cell lysis buffer (50 mM
Tris–HCl, pH 7.5, 0.5 M NaCl, 1% NP-40, 0.1% SDS) supplemented
with protease cocktail (Sigma). Protein concentration of lysates
was measured by Bradford assay (Bio-Rad) and 1.0 mg of total
protein was subjected to IP/Kinase reaction. Immunoprecipita-
tions were carried out with the cell lysate and 5 mg of antibodies
combined with 50 ml of 30% slurry of protein AþG agarose for
12 h at 4 1C in a TNN buffer containing 50 mM Tris–HCl, pH 7.5,
0.15 M NaCl, and 1% NP-40. The agarose beads were precipitated,
washed with TNN buffer and used for the kinase assay. Care was
taken to remove all detergents before the kinase assay. Kinase
assay was performed at 37 1C for 60 min in a kinase assay buffer
(50 mM HEPES-KOH, pH 7.9, 10 mM MgCl2, 6 mM EGTA, 2.5 mM
DTT) containing 1 mg of histone H1 as a substrate, 200 nM cold
ATP, and 5 mCi of (g-32P) ATP. CTD phosphorylation assay was
performed at 32 1C for 30 min in 20 ml of kinase assay buffer
(50 mM HEPES–KOH, pH 7.9, 10 mM MgCl2, 6 mM EGTA, 2.5 mM
DTT) containing 4 mg of CTD substrate, 250 nM cold ATP, and
5 mCi of (g-32P)ATP. Reaction was stopped with SDS-loading
buffer and resolved on 4–20% PAGE. Dried gel was exposed to
phosphorimager screen.
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PBMCs were seeded in 96-well plates at 50,000 cells per well
and the appropriate inhibitors were added. Cell viability was
measured using CellTiter-Glo Cell Luminescence Viability kit
(Promega) as per manufacturer’s instructions. Brieﬂy, an equal
volume of CellTiter-Glo reagent (100 ml) was added to the cell
suspension (100 ml). The plate was shaken for approximately
10 min on an orbital shaker at room temperature following which
luminescence was detected using the GLOMAX multidetection
system (Promega).
Cytoplasmic and nuclear extracts
The cytosolic extracts were prepared by resuspending the cells
in 80 ml of Buffer A with 0.5% NP-40 for 10 min on ice. The nuclei
were spun down at 5000g for 5 min and the supernatant was
saved as the cytosolic extract (CE). The nuclei were washed once
with 200 ml of Buffer A with 0.5% NP-40 and re-pelleted. The
nuclei were resuspended in 80 ml of Buffer B (170) and incubated
on ice for 10 min. The lysates were clariﬁed by centrifugation at
20,000g for 10 min. The sup was saved as the nuclear extract (NE).
Western blotting was performed with 1/5 of the samples and the
fraction of cdk9 in the cytosolic and nuclear extracts was
determined by imaging the chemiluminescent signal on CCD
camera (Bio-Rad).
Western blots
Cell extracts were resolved by SDS PAGE on a 4–20% tris–
glycine gel (Invitrogen). Proteins were transferred to Immobilon
membranes (Millipore) at 200 mA for 2 h. Membranes were
blocked with Dulbecco’s PBSþ0.1% Tween-20þ5% BSA. Primary
antibody against speciﬁed antibodies was incubated with the
membrane in PBSþ0.1% Tween-20 overnight at 4 1C. Membranes
were washed 3 times with PBSþ0.1% Tween-20 and incubated
with HRP-conjugated secondary antibody for 1 h. Presence of
secondary antibody was detected by SuperSignal West Dura
Extended Duration Substrate (Pierce).
Chromatin Immunoprecipitation Assay (ChIP)
Cells were seeded to early–mid log phase of growth and then
processed for ChIP beginning with cross-linking proteins to DNA
by 1.0% formaldehyde. Chromatin was sonicated ﬁve times for
20 s each, generating DNA fragments of about 500–100 base pairs.
The sonicated supernatants containing the DNA were diluted with
ChIP dilution buffer (0.01% SDS, 1% Triton X-100, 1.2 mM EDTA,
16.7 mM Tris–HCl pH 8.1, and 167 mM NaCl) to a total volume of
5.5 ml, and precleared by rotating for one hour at 4 1C with ChIP
prepared protein A/G beads (beads washed twice with 1 ml
TNE50þ0.1% NP-40, resuspended in 650 ml; with addition of
40 ml of ssDNA (10 mg/ml) and 75 ml BSA (10 mg/ml)). No
proteases or RNAses were used for the extraction. The extract
was centrifuged at 3000 rpm for 10 min at 4 1C and the lysate was
transferred to a fresh tube. Supernatant (500 mL) was reserved for
input and then 10 mg of each antibodies indicated above were
added to the reaction mixture. After overnight rotation at 4 1C, the
immune complexes were collected by addition of ChIP prepared
protein A/G beads. After extensive washes, the immune com-
plexes were eluted with 1% SDS/NaHCO3 solution for 30 min at
room temperature. The eluted complexes were treated with NaCl
solution and reverse cross-linked overnight. DNA was extracted
using 1:1 phenol/chloroform (500 ml) followed by addition of 1 ml
of absolute ethanol and 3 M sodium acetate (50 ml) incubated at
20 1C for at least 20–30 min. The solution was spun for 20 minat 14,000 rpm at 4 1C followed by a 70% ethanol wash and 5 min
spin. DNA pellet was resuspended in 1 TE and stored at 4 1C.
Afterwards, DNA was puriﬁed by PCR puriﬁcation Kit (BiONEER)
and ampliﬁed by PCR. Primer pairs for quantitative-PCR analysis
of chromatin immunoprecipitation ampliﬁed sequences ﬂanked
the HIV-1 LTR nuc-1 (þ10 to þ165) and Env (þ8990 to þ9120).
Reverse transcription (RT) assay for presence of virus
Viral supernatants (10 ml) were incubated in a 96-well plate
with reverse transcriptase (RT) reaction mixture containing
1RT buffer (50 mM Tris–HCl, 1 mM DTT, 5 mM MgCl2, 20 mM
KCl), 0.1% Triton, poly(A) (1 U/ml), pd(T) (1 U/ml), and [3H]TTP.
The mixture was incubated overnight at 37 1C, and 10 ml of the
reaction mix was spotted on a DEAE Filtermat paper, washed
4 times with 5% Na2HPO4, 3 times with water, and then dried
completely. RT activity was measured in a Betaplate counter
(Wallac, Gaithersburg, MD). Cells were also processed for western
blot analysis using anti-actin antibodies.
Size-exclusion chromatography
Early–mid log phase HIV-1 infected J1-1 (which produce high
titer RT positive virus present in the media) or uninfected Jurkat
cells were pelleted for analysis. Cell pellets were washed twice
with PBS without Ca2þ and Mg2þand resuspended in lysis buffer
[50 mM Tris–HCl (pH 7.5), 120 mM NaCl, 5 mM ethylenediami-
netetraacetic acid, 0.5% NP-40, 50 mM NaF, 0.2 mM Na3VO4,
1 mM DTT, and one complete protease cocktail tablet/50 ml]
and incubated on ice for 20 min, with gentle vortexing every
5 min. Lysates were then centrifuged at 4 1C at 10,000 rpm for
10 min. Supernatants were transferred to a fresh tube and protein
concentrations were determined using the Bradford protein assay
(BioRad, Hercules, CA). Two milligrams of protein from each
treatment was equilibrated and degassed in chromatography
running buffer [0.2 M Tris–HCl (pH 7.5), 0.5 M NaCl, and 5%
glycerol]. The lysates were run on a Superose 6 h 10/30 size-
exclusion chromatography column using the AKTA puriﬁer sys-
tem (GE Healthcare, Piscataway, NJ, USA). Flow-through was
collected at 4 1C at a ﬂow rate of 0.3 ml/min at 0.5 ml for
approximately 70 fractions. Every 5th fraction was acetone
precipitated using 4 volumes of ice-cold 100% acetone, incubating
for 15 min on ice. Lysates were centrifuged at 4 1C for 10 min at
12,000 rpm, supernatants were removed, and the pellets were
allowed to dry for a few minutes at room temperature. The pellets
were resuspended in Laemmli buffer and analyzed by immuno-
blotting for cyclin T1 (Santa Cruz Biotechnology Inc., H-245), cdk9
(Santa Cruz Biotechnology Inc., C-20), Hexim 1 (Santa Cruz
Biotechnology Inc., H-66), ELL2 (Santa Cruz Biotechnology Inc.,
G-5), Brd4 (Santa Cruz Biotechnology Inc., H-250), p24 (NIH AIDS
Research and Reference Reagent Program, 4121) and b-actin
(Abcam., AB49900). Equal volume of sample fractions (# 14, 31,
and 46) from both Jurkat and J1-1 were loaded on gels prior to
western blots. The protein concentrations for these three fractions
showed a typical bell shape curve where fraction #31 (peak of the
bell) had the most proteins in either Jurkat or J1-1 preps.
Quantitative RT-PCR analysis
Aliquots of the sample fractions (50 ml) harvested after size-
exclusion chromatographyof the lysates of J1.1 and Jurkat cells
were incubated with DNaseI, RNase-Free (Roche)—1 U per sample
for 1 h at 37 1C. DNase was then inactivated at 65 1C for 15 min;
total RNA was isolated using TRI Reagent-LS (MRC, Cincinnati,
OH) according to the manufacturer’s protocol. A 250 ng aliquot of
total RNA was taken for RT reaction to generate cDNA with the
A. Narayanan et al. / Virology 432 (2012) 219–231230GoScript Reverse Transcription System (Promega, Madison, WI)
using 7SK-RTr reverse primer (50–AAAAGAAAGGCAGACTGCC–30).
Subsequent quantitative real-time PCR analysis of 2 ml aliquots of
the RT reaction mixes diluted to 101 and 102 was performed
using iQ SYBR Green Supermix (BioRad, Hercules, CA) with the
following pairs of primers: 7SK-F (50–GACATCTGTCACCCCATTGA–
30) and 7SK-R (50–GCGCAGCTACTCGTATACCC–30) ampliﬁed
184 nt. fragment of the cDNA copy of 7SK snRNA. Real-time PCR
reactions were carried out in duplicate using the PTC-200 Peltier
Thermal Cycler with Chromo4 Continuous Fluorescence Detector
(both from MJ Research) and Opticon Monitor 2.03 software.
Statistical analysis
All quantiﬁcations are based on data obtained from triplicate
experiments. P-values were calculated by Student’s t-test.Acknowledgments
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